
Hancock Jaffe Laboratories, Inc. HJLI
Hancock Jaffe Laboratories, Inc. Deferred Revenue 2011-2025 | HJLI
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Hancock Jaffe Laboratories, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 33 | 33 K | 33 K | 103 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 103 K | 33 | 42.4 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.86 | -3.26 % | $ 134 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Abiomed
ABMD
|
24.3 M | - | - | $ 17.2 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 307.92 | -1.93 % | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 45.13 | -2.67 % | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Boston Scientific Corporation
BSX
|
306 M | $ 92.34 | 0.64 % | $ 136 B | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 2.56 | 8.94 % | $ 95.5 M | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 0.92 | -4.72 % | $ 14.8 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 96.35 | -1.06 % | $ 1.22 B | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
LivaNova PLC
LIVN
|
10.8 M | $ 62.79 | -1.82 % | $ 3.41 B | ||
|
Pulmonx Corporation
LUNG
|
135 K | $ 2.53 | 0.86 % | $ 99 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.56 | 0.76 % | $ 1.15 B | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 9.88 | 0.05 % | $ 709 M | ||
|
Myomo
MYO
|
2.51 K | $ 1.06 | -1.85 % | $ 7.47 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 13.41 | -4.56 % | $ 1.03 B | ||
|
Align Technology
ALGN
|
1.33 B | $ 165.15 | 0.78 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 1.07 | -3.18 % | $ 110 M | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 12.81 | -1.23 % | $ 346 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 14.86 | -0.03 % | $ 97.4 M | ||
|
AxoGen
AXGN
|
14 K | $ 30.33 | 1.15 % | $ 1.34 B | ||
|
LENSAR
LNSR
|
1.68 M | $ 11.48 | -0.17 % | $ 132 M |